Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS
Open Access
- 12 September 2024
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 35 (4) , 102332
Abstract
No abstract availableKeywords
Funding Information
- National Institute on Aging (R56 AG052328-01)
- Barrow Neurological Foundation
- National Institutes of Health
This publication has 53 references indexed in Scilit:
- Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expressionVirology, 2008
- DNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral ProgenyMolecular Therapy, 2008
- Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower dosesProceedings of the National Academy of Sciences, 2008
- Heparan Sulfate Proteoglycan Binding Properties of Adeno-Associated Virus Retargeting Mutants and Consequences for Their In Vivo TropismJournal of Virology, 2006
- Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehiclesNature Protocols, 2006
- Directed evolution of adeno-associated virus yields enhanced gene delivery vectorsNature Biotechnology, 2006
- Green Fluorescent Protein-Tagged Adeno-Associated Virus Particles Allow the Study of Cytosolic and Nuclear TraffickingJournal of Virology, 2005
- Heparan sulphate proteoglycans in Alzheimer's disease and amyloid‐related disordersThe Lancet Neurology, 2003
- Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 VirionsJournal of Virology, 1998
- Developmental and Age‐Related Changes in Rat Brain GlycosaminoglycansJournal of Neurochemistry, 1988